Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.55 |
| ▸ | ELOC | Q15369 | 1/20 | 0.55 |
| ▸ | ELOB | Q15370 | 1/20 | 0.55 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | GRK2 | P25098 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AOC2 | O75106 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20780661 | 0.84 | VHL (0.52) | VHLELOCELOBACACBPOLB | |
| SCHEMBL21983905 | 0.82 | VHL (0.50) | VHLELOCELOBACACBPOLB | |
| SCHEMBL278317 | 0.79 | AOC2 (0.47) | VHLELOCELOBACACBAOC2 | |
| SCHEMBL1131597 | 0.76 | PTGS1 (0.56) | POLBMEN1KMT2ALMNABLM | |
| SCHEMBL10130598 | 0.76 | LMNA (0.53) | MEN1KMT2ALMNAMAPTCYP2C9 | |
| SCHEMBL5603565 | 0.76 | VHL (0.61) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL20319186 | 0.75 | VHL (0.67) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL14210016 | 0.75 | POLB (0.62) | VHLELOCELOBACACBPOLB | |
| SCHEMBL11835877 | 0.75 | POLB (0.53) | VHLELOCELOBACACBPOLB | |
| SCHEMBL22485643 | 0.74 | GABRA1 (0.35) | ACACBLMNABLMFAAHPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2942346-B1 | PYRIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-10-26 | — | — | US | disclosed |
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-10-26 | — | — | US | disclosed |
| US-9040563-B2 | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8981106-B2 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8748623-B2 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | YALE UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | VHL 1987/4885ELOC 2749/4885ELOB 1607/4885 |
| US-20170305893-A1 | HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS | DCTPP1, ENPP1, PPA1 | VHL 308/4885ELOC 3119/4885ELOB 3364/4885 |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | SREBF1, SREBF2, BPTF | VHL 1816/4885ELOC 2377/4885ELOB 367/4885 |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | CXCR2, CXCR1, CXCR3 | VHL 1678/4885ELOC 2808/4885ELOB 1382/4885 |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | CXCR2, CXCR1, CXCR3 | VHL 1437/4885ELOC 3391/4885ELOB 1669/4885 |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | FNTA, FNTB, GDI1 | VHL 279/4885ELOC 2191/4885ELOB 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.